Pediatrix Medical (MD) Cash & Equivalents (2009 - 2026)

Pediatrix Medical has disclosed Cash & Equivalents across 18 years of filings, most recently posting $205.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 107.9% year-over-year to $205.8 million; the TTM figure through Mar 2026 stood at $205.8 million (up 107.9% YoY), while the FY2025 annual figure was $375.2 million, up 63.19% from the prior year.
• Cash & Equivalents eased to $205.8 million in Q1 2026, from $375.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MD reached as high as $375.2 million in Q4 2025 and fell as low as $5.8 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $21.2 million (2023), against an average of $103.1 million.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 97.58% — and 2025, when it surged 1137.53%.
• A 5-year view of Cash & Equivalents shows it stood at $9.8 million in 2022, then jumped by 645.7% to $73.3 million in 2023, then surged by 213.88% to $229.9 million in 2024, then soared by 63.19% to $375.2 million in 2025, then plunged by 45.16% to $205.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $205.8 million, $375.2 million, and $340.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.